Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06560645 · ClinicalTrials.gov registry record · Phase 1
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
A Phase 1 study, sponsored by Prelude Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT06560645 is a Phase 1 study that was terminated before completion, run by Prelude Therapeutics. The registered enrollment target is 42 participants.
The verdict
NCT06560645, a Phase 1 study, was terminated before completion, sponsored by Prelude Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a Phase 1 study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRT7732 in patients with select advanced or metastatic solid tumors with a SMARCA4 mutation.
Interventions
- DRUG PRT7732
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2024-11-04 |
| Est. Completion | 2026-01-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06560645
The ClinicalTrials.gov registry entry for NCT06560645 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prelude Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRT7732 is the first listed.
NCT06560645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06560645 about?
NCT06560645 is a clinical study titled "A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation". This is a Phase 1 study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRT7732 in patients with select advanced or metastatic solid tumors with a SMARCA4 mutation.
What is the current status of trial NCT06560645?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2024-11-04. Estimated completion is 2026-01-28.
What interventions are being tested in trial NCT06560645?
The interventions under investigation include: PRT7732 (DRUG).
Who is sponsoring clinical trial NCT06560645?
This trial is sponsored by Prelude Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.